Heghine Khachatryan: 2026 AHA Guideline on the Management of CKM Syndrome
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared American Heart Association’s post on LinkedIn, adding:
“The publication of the 2026 American Heart Association (AHA) Guideline on the Management of Cardiovascular–Kidney–Metabolic (CKM) Syndrome represents another important step toward precision cardiovascular prevention.
The guideline emphasizes that cardiovascular, renal, and metabolic diseases should no longer be approached as isolated entities but rather as interconnected components of a unified pathophysiological continuum.
This is an important paradigm shift.
As hematologists and thrombosis specialists, we increasingly manage patients whose thrombotic risk is closely intertwined with metabolic dysfunction, chronic kidney disease, and cardiovascular pathology.
Incorporating standardized cardiovascular risk prediction into multidisciplinary care can facilitate earlier prevention strategies and improve outcomes in high-risk populations.”
American Heart Association shared a post on LinkedIn:
“The 2026 Guideline on the Management of CKM Syndrome was recently published.
Individuals at risk for cardiovascular disease (CKM syndrome stage 0-3) should have their risk quantified with the PREVENT (Predicting Risk of cardiovascular disease EVENTs) equations to estimate 10- and 30-year risk for atherosclerotic cardiovascular disease, heart failure, and total CVD.
PREVENT estimates inform CKM syndrome staging, with greater than or equal to 20% predicted 10-year CVD risk serving as one criterion for CKM syndrome Stage 3. A greater than or equal to 7.5% predicted 10-year CVD risk further informs the prioritization of pharmacotherapies”
Other posts featuring Heghine Khachatryan on Hemostasis Today.
-
Jul 3, 2026, 12:32Shadi Tabibian: Beyond Bleeding – Women Living with von Willebrand Disease
-
Jul 3, 2026, 09:33Abdul Mannan: Not All Type 1 VWD Starts in the VWF Gene
-
Jul 3, 2026, 09:18Aryabhatta Sadhu: Sickle Cell Crisis – When Diagnostics Should Change Therapy
-
Jul 3, 2026, 05:55New Evidence Supports Chromogenic Assays After Hemophilia A Gene Therapy – JTH
-
Jul 3, 2026, 05:50Jacopo Parizzi: Roche’s Non-Malignant Hematology Team Is Looking Ahead to 2027
-
Jul 3, 2026, 05:25Brian A Beh: A New Approach from The George Institute for Global Health Could Transform Stroke Care Before Hospital Arrival
-
Jul 3, 2026, 05:22Deirdre Finnigan: New Insights into Red Blood Cell Biomechanics in Cancer-Associated Anemia
-
Jul 3, 2026, 05:15Danielle Boyle: Collaboration Across Borders Is Helping Shape the Future of ITP Care
-
Jul 3, 2026, 05:05Claire McIvor: One Year at the Stroke Association and Grateful for a Workplace That Made It Possible